Possibility of a New Indication for Amantadine in the Treatment of Bipolar Depression—Case Series Study

Krzystanek, Marek; Pałasz, Artur

doi:10.3390/ph13100326

Cited by 9 publications

(8 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…b. Amantadine stimulates dopamine release and prevents dopamine reuptake. COMT = Catechol-O-transferase; DA = dopamine; MAO = monoamine oxidase (Source-Medscape) [ 48 , 51 ]. …”

Section: Neurological Diseasesmentioning

confidence: 99%

Drug repositioning: Progress and challenges in drug discovery for various diseases

Dai

et al. 2022

European Journal of Medicinal Chemistry

103

View full text Add to dashboard Cite

“…b. Amantadine stimulates dopamine release and prevents dopamine reuptake. COMT = Catechol-O-transferase; DA = dopamine; MAO = monoamine oxidase (Source-Medscape) [ 48 , 51 ]. …”

Section: Neurological Diseasesmentioning

confidence: 99%

Drug repositioning: Progress and challenges in drug discovery for various diseases

Dai

et al. 2022

European Journal of Medicinal Chemistry

103

View full text Add to dashboard Cite

“…Amantadine may influence serotoninergic pathways, increasing serotonin availability. In rat models, this drug increases serotonin release and inhibits serotonin reuptake in presynaptic neurons [ 23 , 24 ]. One of the hypotheses for the pathophysiology of myoclonus is related to serotonin augmentation in the cerebellar output [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

Myoclonus Secondary to Amantadine: Case Report and Literature Review

Rissardo

Caprara

2023

Clinics and Practice

View full text Add to dashboard Cite

The usual adverse events of amantadine are dizziness, dry mouth, and peripheral edema. Postmarketing experience has revealed abnormal movements such as tremors, involuntary muscle contractions, and gait abnormalities. Herein, we report a case of an elderly male who presented with generalized twitching associated with amantadine. A 64-year-old male presenting with jerking movements within one day of onset was admitted. Sudden and involuntary distal lower and upper limb muscle twitching was observed. The subject presented subsequent brief movements when attempting to stand or hold arms antigravity. He was diagnosed with Parkinson’s disease three years ago. Eight days before the presentation to the emergency department, he consulted with his primary care physician, who prescribed amantadine to improve his motor symptoms. On the seventh day, he developed brisk abnormal movements. Laboratory exams, neuroimaging, and electroencephalogram were unremarkable. Amantadine was discontinued. After three days, the patient reported that his jerking movements had fully recovered. To the authors’ knowledge, 22 individuals with amantadine-associated myoclonus had already been reported in the literature. The pathophysiology of amantadine-induced myoclonus is probably related to serotoninergic pathways. Myoclonus secondary to amantadine was slightly more common in men. The population affected was elderly, with a mean and median age of 67.7 and 64 years.

show abstract

“…In a very recent case study, amantadine (100 or 200 mg daily) improved depressive symptoms in four bipolar I disorder patients resistant to common antidepressants (Krzystanek and Palasz 2020 ).…”

Section: Preclinical and Clinical Evaluation Of Amantadine’s Non-canomentioning

confidence: 98%

Amantadine: reappraisal of the timeless diamond—target updates and novel therapeutic potentials

et al. 2021

View full text Add to dashboard Cite

The aim of the current review was to provide a new, in-depth insight into possible pharmacological targets of amantadine to pave the way to extending its therapeutic use to further indications beyond Parkinson’s disease symptoms and viral infections. Considering amantadine’s affinities in vitro and the expected concentration at targets at therapeutic doses in humans, the following primary targets seem to be most plausible: aromatic amino acids decarboxylase, glial-cell derived neurotrophic factor, sigma-1 receptors, phosphodiesterases, and nicotinic receptors. Further three targets could play a role to a lesser extent: NMDA receptors, 5-HT3 receptors, and potassium channels. Based on published clinical studies, traumatic brain injury, fatigue [e.g., in multiple sclerosis (MS)], and chorea in Huntington’s disease should be regarded potential, encouraging indications. Preclinical investigations suggest amantadine’s therapeutic potential in several further indications such as: depression, recovery after spinal cord injury, neuroprotection in MS, and cutaneous pain. Query in the database http://www.clinicaltrials.gov reveals research interest in several further indications: cancer, autism, cocaine abuse, MS, diabetes, attention deficit-hyperactivity disorder, obesity, and schizophrenia.

show abstract

Possibility of a New Indication for Amantadine in the Treatment of Bipolar Depression—Case Series Study

Cited by 9 publications

References 42 publications

Drug repositioning: Progress and challenges in drug discovery for various diseases

Drug repositioning: Progress and challenges in drug discovery for various diseases

Myoclonus Secondary to Amantadine: Case Report and Literature Review

Amantadine: reappraisal of the timeless diamond—target updates and novel therapeutic potentials

Contact Info

Product

Resources

About